A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A

Takeda

Status

Enrolling

Conditions

Acquired Hemophilia A

Treatments

Drug: Susoctocog Alfa (Genetical Recombination)

Study type

Observational

Funder types

Industry

Identifiers

NCT06461533

TAK-672-4004

Details and patient eligibility

About

This study is a survey in Japan of Susoctocog Alfa (Genetical Recombination) intravenous injection used to treat participants with bleeding events of acquired Haemophilia A (AHA). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

The main aim of the study is to check for side effects related from Susoctocog Alfa (Genetical Recombination) intravenous injection and to check if Susoctocog Alfa (Genetical Recombination) intravenous injection improves bleeding events of AHA.

During the study, participants with AHA will take Susoctocog Alfa (Genetical Recombination) intravenous injection according to their clinic's standard practice. The study doctors will check for side effects from Susoctocog Alfa (Genetical Recombination) intravenous injection for up to 90 days after the last dose of study drug or until discontinued (varied from participant to participant).

Enrollment

25 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria